ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0151

More Than Half of Newly Diagnosed RA Patients Are Not Convinced of the Necessity of RA Medicines: Associations with RA Characteristics, Symptoms, and Function in the Canadian Early Arthritis Cohort (CATCH)

Viviane Ta1, Orit Schieir2, Marie-France Valois3, Diane Tin4, Carol Hitchon5, Louis Bessette6, Carter Thorne4, Janet Pope7, Gilles Boire8, Edward Keystone9, Vivian Bykerk10, Susan Bartlett3 and Canadian Early Arthritis Cohort (CATCH) Investigators11, 1McGill University, Montreal, QC, Canada, 2Canadian Early Arthritis Cohort Study, Montreal, Canada, 3McGill University, Montreal, Canada, 4Southlake Regional Health Centre, Newmarket, ON, Canada, 5University of Manitoba, Winnipeg, MB, Canada, 6Laval University, Quebec, Canada, 7Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, 8Universite de Sherbrooke, Sherbrooke, Canada, 9The Rebecca MacDonald Centre for Arthritis, Mt. Sinai Hospital, Toronto, Canada, 10Hospital for Special Surgery, New York, NY, 11Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada

Meeting: ACR Convergence 2020

Keywords: health behaviors, Patient reported outcomes, prognostic factors, psychosocial factors, quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Although DMARDs are essential for early aggressive control of RA to reduce symptoms and disability, medication adherence is variable. Beliefs about the necessity of medications and safety concerns predict adherence and are modifiable. Little is known about perceptions of RA medications in patients who are newly diagnosed. We examined associations among RA medication necessity beliefs and concerns, sociodemographics, RA characteristics, symptom levels and function in new RA patients around the time of diagnosis and starting medications.

Methods: Baseline data were analyzed from participants in the Canadian Early Arthritis Cohort (CATCH) who enrolled between 2017-2020 and completed the Beliefs about Medicine Questionnaire (BMQ) and PROMIS-29. All met ACR1987 or 2010 ACR/EULAR criteria and had active RA at enrollment. BMQ Necessity (N) and Concerns (C) scores were classified as high (≥20) or low (< 20) and categorized into: Accepting (↑N ↓C); Ambivalent (↑N↑C); Sceptical (↓N↑C); and 4) Indifferent (↓N↓C). Groups were compared using ANOVA and chi-square tests.

Results: The 362 patients were mostly white (83%) women (66%) with a mean (SD) age of 56 (15), symptom duration of 6 (3) months, and 32% were obese (BMI≥30).  More than half (56%) were DMARD-naive or minimally exposed. Mean N and C scores were similar between men and women; 54% were classified as Indifferent, 31% Accepting, 9% Ambivalent, and 6% Sceptical (Table 1). As compared to those classified as Accepting, more Indifferent participants smoked, had a healthy weight, lower TJCs, and trend for lower CDAI (Table 1). Groups were similar by sociodemographics, symptom duration, and DMARD/steroid use, except fewer Indifferent patients received MTX.

Most (67-100%) worried about the long-term effects of their medications (Table 2). Indifferent patients had statistically and meaningfully lower patient global, depression, anxiety, fatigue and pain interference, and higher function and participation scores (Table 3). 

Conclusion: Most new RA patients worried about the long-term safety of their RA medications. Many had low medication necessity beliefs and concerns, and only 31% had high necessity beliefs and low concerns around diagnosis. Lifestyle and lower CDAI, TJCs, symptoms and functional impacts were associated with RA medication indifference. Exploring medication beliefs in newly diagnosed RA patients may help identify information gaps and provide opportunities to address concerns, potentially improving adoption and persistence over time.

Table 1. Patient characteristics at baseline by profiles.

Table 2. Proportions of patients who agreed/strongly agreed with each item.

Table 3. Physical, emotional, and social function by BMQ attitudinal profiles.


Disclosure: V. Ta, None; O. Schieir, None; M. Valois, None; D. Tin, None; C. Hitchon, None; L. Bessette, Amgen, 1, 2, 3, BMS, 1, 2, 3, Janssen, 1, 2, 3, UCB, 1, 2, 3, AbbVie, 1, 2, 3, Pfizer, 1, 2, 3, Merck, 1, 2, 3, Celgene, 1, 2, 3, Sanofi, 1, 2, 3, Lilly, 1, 2, 3, Novartis, 1, 2, 3, Gilead, 2, 6, 8; C. Thorne, Abbvie, 1, 2, Amgen, 1, 2, Celgene, 1, 2, CaREBiodam, 1, Centocor, 1, Janssen, 1, Lilly, 1, Medexus/Medac, 1, 2, Merck, 1, Novartis, 1, 2, Pfizer, 1, 2, Sanofi, 1; J. Pope, AbbVie, 2, 5, Amgen, 5, 8, Lilly, 2, 5, 8, UCB, 2, 5, 8, Sanofi, 5, 8, Sandoz, 5, 8, Roche, 2, 5, 8, Pfizer, 5, 8, Novartis, 5, 8, Merck, 2, 5, 8, Janssen, 5, 8, Gilead Sciences, Inc., 2, 5, BMS, 2, 5, 8, Abbott, 5, Actelion, 5, AstraZeneca, 5, Bayer, 5, Boehringer Ingelheim, 5, EICOS, 5, Emerald, 5, GlaxoSmithKline, 5, Medexus, 5, Seattle Genetics, 2; G. Boire, Amgen, 1, 2, BMS, 1, 2, 3, Celgene, 1, Merck, 1, 2, Pfizer, 1, 2, 3, Eli Lilly, 1, 2, Janssen, 1, Abbvie, 1, Novartis, 1, Sandoz, 1; E. Keystone, Abbot, 2, 5, 8, Amgen, 2, 5, 8, AstraZeneca, 2, 5, 8, Biotest, 2, 5, 8, Bristol-Myers Squibb, 2, 5, 8, F. Hoffmann-La Roche Inc., 2, 5, 8, Janssen, 2, 5, 8, Eli Lilly and Company, 2, 5, 8, Genentech, 2, 5, 8, Merck, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Sanofi-Aventis, 2, 5, 8, UCB, 2, 5, 8; V. Bykerk, Amgen, 2, 5, UCB, 5, National Institute of Health, 2, 9, Bristol-Myers Squibb Company, 2, 5, Gilead, 5, Pfizer, 5, Brainstorm Therapeutics, 1, 3; S. Bartlett, Pfizer, 1, UCB, 1, Lily, 1, Novartis, 1, Merck, 1, Janssen, 1, Abbvie, 1; C. (CATCH) Investigators, Amgen, 2, Pfizer Canada, 2, Medexus Inc., 2, Eli Lilly Canada, 2, Merck Canada, 2, Sandoz Canada, Biopharmaceuticals, 2, Gilead Sciences Canada, 2, Hoffmann-LaRoche, 2, Janssen Biotech, 2, UCB Canada, 2, Bristol-Myers Squibb Canada, 2, Sanofi Genzyme, 2, AbbVie Corporation, 2.

To cite this abstract in AMA style:

Ta V, Schieir O, Valois M, Tin D, Hitchon C, Bessette L, Thorne C, Pope J, Boire G, Keystone E, Bykerk V, Bartlett S, (CATCH) Investigators C. More Than Half of Newly Diagnosed RA Patients Are Not Convinced of the Necessity of RA Medicines: Associations with RA Characteristics, Symptoms, and Function in the Canadian Early Arthritis Cohort (CATCH) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/more-than-half-of-newly-diagnosed-ra-patients-are-not-convinced-of-the-necessity-of-ra-medicines-associations-with-ra-characteristics-symptoms-and-function-in-the-canadian-early-arthritis-cohort-c/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/more-than-half-of-newly-diagnosed-ra-patients-are-not-convinced-of-the-necessity-of-ra-medicines-associations-with-ra-characteristics-symptoms-and-function-in-the-canadian-early-arthritis-cohort-c/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology